FDA approves changes to Byetta label
The FDA approved a revised label for diabetes drug Byetta to include reports of problems with kidney function. The decision came days after Eli Lilly and Co. and Amylin Pharmaceuticals received clearance to promote Byetta as a stand-alone treatment for Type 2 diabetes.
Wall Street Journal, The
| 11/2
This story published in FMI Pharmacy dailyLead on 11/03/2009
Get stories like these delivered daily for FREE:
|
FMI Pharmacy dailyLead
Designed specifically for pharmacy professionals, FMI Pharmacy dailyLead is a FREE, daily e-mail newsletter. It provides the latest news in the pharmacy arena. Learn more |
|